Last reviewed 2026-05-30 · How we verify

RiMO-301

Coordination Pharmaceuticals, Inc. · Phase 1 active Small molecule ✓ Verified May 2026

RiMO-301 is a Small molecule drug developed by Coordination Pharmaceuticals, Inc.. It is currently in Phase 1 development. Also known as: Radiotherapy.

RiMO-301 is a small molecule being studied as a potential treatment for head and neck cancer, particularly in advanced tumors. It is being investigated in combination with radiotherapy and a PD-1 inhibitor in a Phase 1b/2a clinical trial.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	RiMO-301
Also known as	Radiotherapy
Sponsor	Coordination Pharmaceuticals, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer (PHASE1, PHASE2)
Phase I Study of RiMO-301 With Radiation in Advanced Tumors (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

RiMO-301 CI brief — competitive landscape report
RiMO-301 updates RSS · CI watch RSS
Coordination Pharmaceuticals, Inc. portfolio CI

Frequently asked questions about RiMO-301

What is RiMO-301?

RiMO-301 is a Small molecule drug developed by Coordination Pharmaceuticals, Inc..

Who makes RiMO-301?

RiMO-301 is developed by Coordination Pharmaceuticals, Inc. (see full Coordination Pharmaceuticals, Inc. pipeline at /company/coordination-pharmaceuticals-inc).

Is RiMO-301 also known as anything else?

RiMO-301 is also known as Radiotherapy.

What development phase is RiMO-301 in?

RiMO-301 is in Phase 1.

Manufacturer: Coordination Pharmaceuticals, Inc. — full pipeline
Also known as: Radiotherapy

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing